| EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor |
|
| CHEBI:35664 |
|
| Any EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD+ or NADP+ acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
| α-Tocopherol (alpha-tocopherol) is a type of vitamin E. Its E number is "E307". Vitamin E exists in eight different forms, four tocopherols and four tocotrienols. All feature a chromane ring, with a hydroxyl group that can donate a hydrogen atom to reduce free radicals and a hydrophobic side chain, along with an aromatic ring is situated near the carbonyls in the fatty acyl chains of the phospholipid bilayer, allows for penetration into biological membranes. It is found most in the membrane's non-raft domains, associated with omega-3 and 6 fatty acids, to partially prevent oxidation. The most prevalent form, α-tocopherol, is involved in molecular, cellular, biochemical processes closely related to overall lipoprotein and lipid homeostasis. Compared to the others, α-tocopherol is preferentially absorbed and accumulated in humans.
Vitamin E is found in a variety of tissues, being lipid-soluble, and taken up by the body in a wide variety of ways. Ongoing research is believed to be "critical for manipulation of vitamin E homeostasis in a variety of oxidative stress-related disease conditions in humans." One of these disease conditions is the α-tocopherol role in the use by malaria parasites to protect themselves from the highly oxidative environment in erythrocytes. A second of these disease conditions is the α-tocopherol antioxidant properties' role cardiovascular heart disease. In preventing LDL (low-density lipoprotein) oxidation, it is able to decrease chances of atherosclerosis and arterial build-up. |
|
Read full article at Wikipedia
|
|
Outgoing
|
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
is a
EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD+ or NADP+ acceptor) inhibitor
(CHEBI:76835)
|
|
|
Incoming
|
3,3,5-trimethylcyclohexanol
(CHEBI:59065)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
3-hydroxy-3-methylglutaric acid
(CHEBI:16831)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
compactin diol lactone
(CHEBI:34652)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
mevinic acid
(CHEBI:39508)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
mevinolinic acid
(CHEBI:82985)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
ML-236C
(CHEBI:34828)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
monacolin J
(CHEBI:79034)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
monacolin L
(CHEBI:50130)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
simvastatin
(CHEBI:9150)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
statin
(CHEBI:87631)
has role
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
(CHEBI:35664)
|
|
HMG-CoA reductase inhibitor
|
ChEBI
|
|
HMG-CoA reductase inhibitors
|
ChEBI
|
|
hydroxymethylglutaryl-CoA reductase inhibitor
|
ChEBI
|
|
hydroxymethylglutaryl-CoA reductase inhibitors
|
ChEBI
|
|
1464741
|
PubMed citation
|
Europe PMC
|
|
15531285
|
PubMed citation
|
Europe PMC
|
|
20467214
|
PubMed citation
|
Europe PMC
|
|
